Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Tesch

Showing results (51-60 of 282) with videos related to

Pageof 29
Sort By:
Journal of Immunological Methods|January 20, 1998
Single-step purification of bispecific monoclonal antibodies for immunotherapeutic use by hydrophobic interaction chromatographyO Manzke, H Tesch, V Diehl, et al.
European Journal of Immunology|December 1, 1982
The immune response against anti-idiotope antibodies. I. Induction of idiotope-bearing antibodies and analysis of the idiotope repertoireT Takemori, H Tesch, M Reth, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1996
Current clinical trials in Hodgkin's diseaseK Reuss, A Engert, H Tesch, et al.
Medizinische Klinik (Munich, Germany : 1983)|December 15, 1991
[HIV-associated non-hodgkin lymphoma. Prognosis and therapeutic options]M Schrappe, C Pohl, H Tesch, et al.
Hematological Oncology|May 1, 1995
IL6 and IL6 receptor expression in Burkitt's lymphoma and lymphoblastoid cell lines: promotion of IL6 receptor expression by EBVS C Klein, M Jücker, H Abts, et al.
Physiological Reports|September 20, 2019
Establishing equivalent diabetes in male and female Nos3-deficient mice results in a comparable onset of diabetic kidney injuryLifang Tian, David J Nikolic-Paterson, Greg H Tesch
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 1999
Lymphocyte predominant Hodgkin's disease: pathology and clinical implicationJ Franklin, H Tesch, M L Hansmann, et al.
Biochemical and Biophysical Research Communications|December 18, 2007
c-Jun amino terminal kinase 1 deficient mice are protected from streptozotocin-induced islet injuryKyoichi Fukuda, Greg H Tesch, David J Nikolic-Paterson
Genes and Immunity|February 24, 2001
The AT-rich region between -54 to -66 is important for the promoter activity of interleukin-10 in Epstein-Barr virus positive Burkitt's lymphoma cellsD Kube, H Laser, A von Knethen, et al.
Anticancer Research|November 1, 1989
Monoclonal B cell proliferation in lymphoproliferative disease associated with herpes virus type 6 infectionF Berthold, G R Krueger, H Tesch, et al.
Pageof 29

Showing results (51-60 of 282) with videos related to

Sort By:
Pageof 29
Journal of Immunological Methods|January 20, 1998
Single-step purification of bispecific monoclonal antibodies for immunotherapeutic use by hydrophobic interaction chromatographyO Manzke, H Tesch, V Diehl, et al.
European Journal of Immunology|December 1, 1982
The immune response against anti-idiotope antibodies. I. Induction of idiotope-bearing antibodies and analysis of the idiotope repertoireT Takemori, H Tesch, M Reth, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1996
Current clinical trials in Hodgkin's diseaseK Reuss, A Engert, H Tesch, et al.
Medizinische Klinik (Munich, Germany : 1983)|December 15, 1991
[HIV-associated non-hodgkin lymphoma. Prognosis and therapeutic options]M Schrappe, C Pohl, H Tesch, et al.
Hematological Oncology|May 1, 1995
IL6 and IL6 receptor expression in Burkitt's lymphoma and lymphoblastoid cell lines: promotion of IL6 receptor expression by EBVS C Klein, M Jücker, H Abts, et al.
Physiological Reports|September 20, 2019
Establishing equivalent diabetes in male and female Nos3-deficient mice results in a comparable onset of diabetic kidney injuryLifang Tian, David J Nikolic-Paterson, Greg H Tesch
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 1999
Lymphocyte predominant Hodgkin's disease: pathology and clinical implicationJ Franklin, H Tesch, M L Hansmann, et al.
Biochemical and Biophysical Research Communications|December 18, 2007
c-Jun amino terminal kinase 1 deficient mice are protected from streptozotocin-induced islet injuryKyoichi Fukuda, Greg H Tesch, David J Nikolic-Paterson
Genes and Immunity|February 24, 2001
The AT-rich region between -54 to -66 is important for the promoter activity of interleukin-10 in Epstein-Barr virus positive Burkitt's lymphoma cellsD Kube, H Laser, A von Knethen, et al.
Anticancer Research|November 1, 1989
Monoclonal B cell proliferation in lymphoproliferative disease associated with herpes virus type 6 infectionF Berthold, G R Krueger, H Tesch, et al.
Pageof 29